Nov 24, 2014 - Denver Business Journal TechFlash: 'Colorado bioscience organization searches for new leadership'
Quoting from today's Denver Business Journal posting by Greg Avery:
Colorado Institute for Drug, Device and Diagnostic Development is looking for a new CEO in advance of the retirement of Kevin
Smith, the nonprofit group's current leader.
Smith is a co-founding executive of the Aurora-based
nonprofit, known as CID4, that was started to help fill a gap in funding for bioscience startups. CID4 identifies and helps
fund early-stage Colorado bioscience companies that have the potential to grow and create local jobs.
a former president of Gambro U.S.A., a Lakewood-based medical device company, plans to retire Dec. 31. He'll be available
to the organization through February to help in the transition, the organization said. The CID4 board has formed a CEO search
Nov 24, 2014 - Well-known Life Science Executive Kevin M. Smith to Retire as President/CEO of Colorado Institute for Drug,
Device and Diagnostic Development; Search Committee Formed to Hire Smith’s Successor
Kevin M. Smith to Retire as President & CEO of the Colorado Institute for Drug, Device and Diagnostic
Development; Search Committee Formed to Hire Smith’s Successor
The Colorado Institute for
Drug, Device and Diagnostic Development (CID4) has begun a search for a new Executive Director, as Kevin M. Smith leaves as
part of a planned retirement. Mr. Smith will remain with CID4 through February 2015 to ensure a smooth and successful transition
for CID4’s new leader. Aurora, CO November 24,
2014 – Kevin M. Smith, President and CEO of the Colorado Institute for Drug, Device and Diagnostic
Development (CID4) since 2010, will retire from his position as Chief Executive Officer on December 31, 2014. The announcement
is made by Steve Orndorff, PhD, Chairman of the CID4 Board and President & CEO of MicroBiome Therapeutics, who says the
CID4 Board has formed a search committee and that Smith will be available through February 2015 to assist in a smooth transition
for the new Executive Director.
“With the ongoing changes in the healthcare and life science
sectors, CID4 is revisiting how it can best support our industry,” Orndorff said. “CID4 is well positioned for
its future and we believe the new Executive Director position will strengthen our alignment with the State of Colorado in
our mutual quest to create new jobs and business opportunities within the dynamic life science sector of advanced industries.”
All inquiries should be directed to the ‘CID4 Search Committee’ at firstname.lastname@example.org.
The deadline for applications is December 20, 2014. Principals only need apply,
About Kevin M. Smith, CID4 President/CEO
Smith was part
of the team that founded CID4 in 2009. Prior to CID4, Smith was President of Gambro, Inc., the U.S. holding company for Gambro
AB, the Sweden-based medical device and healthcare services company. He started his career with Arthur Young in New York and
was a partner with Ernst & Young, leading the development of their Colorado life science practice at the time he left
to join Gambro.
“While I will no longer be leading CID4, I will stay active in the
Colorado life science community through my Board responsibilities at the Colorado BioScience Association, Donor Alliance and
AlloSource, my service on the Centura Health Audit and Corporate Responsibility Committee and my investment activities at
KMG Capital Partners LLC,” Smith said. “CID4’s success is grounded in the excellent technologies that are
being developed in Colorado. We have invested approximately $3 million into nine early stage companies. Those firms have gone
on to create 85 new jobs and raise an additional $30 million to support the commercialization of their patient-focused technologies.
I am proud to have played a role in this process.”
About the Colorado Institute for Drug, Device and Diagnostic Development
in 2009, the Colorado Institute for Drug, Device and Diagnostic Development (CID4) is a 501(c)(3) not-for-profit charitable
organization whose mission is to advance the Colorado bioscience ecosystem through company creation and job growth. Active
business management and capital work in tandem to help bridge the gap between discovery and product development. CID4 works
to identify, fund and actively manage emerging life science technologies. This aim is achieved via an ongoing technology solicitation
process augmented by additional deal flow sourcing through networked relationships. Active due diligence is provided by CID4
management in consultation with members of the CID4 Technical and Business Advisory Committee. For more information visithttp://CID4.com.
Kevin M. Smith, President/CEO CID4, http://CID4.com -
email@example.com, (720) 859-4047
November Focus Newsletter: Featuring DaVita Clinical Research & CBSA 2014 Award Winners
The November Colorado BioScience Focus Newsletter is now available, with DaVita
Clinical Research as the Company Spotlight and a full overview of the 2014
CBSA Award Winners.
"DaVita Clinical Research (DCR) brings a track
record of success to your Phase I studies. For more than 25 years, DaVita has helped over 150 biopharmaceutical and device
clients successfully manage and execute early phase clinical trials in both healthy normal volunteers and patient populations.
DaVita's integrated clinical data analysis and reporting offering allows for effective and timely decisions about safety and
efficacy." Link to read full the article Link to download the entire November Focus Newsletter.
Colorado BioScience Association Showcases Industry’s Best at 2014 Awards Dinner Celebration
Colorado BioScience Association (CBSA) announced winners of its 11th annual industry awards at the Marriott
City Center, Denver, on November 6. The announcement is made by April Giles, CBSA President and CEO, who opened the evening
with an overview of this year’s industry accomplishments.
Giles was joined by 850
KOA’s Steffan Tubbs and CBSA Board Chair Derek Cole, announcing the following winners:
Company of the Year: AlloSource
AlloSource, based in Centennial, is committed
to its success and growth in Colorado’s bioscience community. Expanding its Colorado headquarters by 90,000 square feet
in 2012, the company continued the momentum in 2013 by launching a new proprietary allograft used in a broad range of soft
tissue surgical procedures. Most recently in 2014, AlloSource announced two new partnerships which will expand their work
in stem cell innovation as well as undertake a new project with NASA through the Space Act Agreement. This work will advance
microbial research in tissue processing for various Mars missions. Visit: http://www.allosource.org .
Finalists for Company of the Year were: Mountainside Medical, Boulder, http://mountainsidemed.com and
Spectranetics, Colorado Springs, http://www.spectranetics.com.
Rising Star of the Year: ViroCyt
ViroCyt, Boulder, launched the
first Virus Counter in 2011, which has proven to be faster, more accurate and cost effective than traditional viral quantification
methods with results in minutes instead of days or weeks. This year ViroCyt announced the introduction of the next generation
Virus Counter at the World Vaccine Congress held in Washington, DC. The technology has already been adopted by the leading
companies in the fields of viral vaccine development and therapeutic protein expression. Virocyt’s innovations are changing
the landscape of virus detection technologies. Visit: http://virocyt.com.
Finalists for Rising Star were: JustRight Surgical, Boulder, http://www.justrightsurgical.com and
Silvergate Pharmaceuticals, Greenwood Village, http://www.silvergatepharma.com.
Lifetime Achievement: Dr. Richard Duke
Dr. Duke is an accomplished scientist
with over 25 years of experience in cutting-edge biomedical research, and is a tenured faculty member in the Departments of
Medicine and Immunology at the University of Colorado Denver. He has been instrumental in the development of Colorado’s
bioscience industry as an executive, inventor, biomedical researcher and serial entrepreneur. Dr. Duke was involved in the
formation and management of GlobeImmune, Newellink USA, ApopLogic Pharmaceuticals, Sierra Neuropharmaceuticals, PeptiVir,
MenoGeniX and Aurora Oncology. He has also been integral to these Colorado-based companies, by raising more than $200 million
in financing and helped bring multiple products to human clinical trials.
One of the Colorado bioscience
industry’s proudest achievements was the creation of the BioScience Discovery Evaluation Grant Program (also referred
to as BDEG). Dr. Duke was the visionary and driving force behind the development of BDEG, making the program what it is today.
This initial concept in 2006 has now become a national model for state’s trying to cultivate a bioscience industry of
Institute Leadership: Jim Rosa
During last year’s
Awards Dinner, CBSA introduced a new award, the Institute Leadership award. This award was created to recognize outstanding
efforts that further the Colorado Bioscience Institute’s mission of providing education, workforce and career development
for life science professionals, companies, students and teachers. This year, CBSA honors one outstanding Institute champion,
Jim Rosa, for his leadership on the workforce training programs. The workforce training programs involve partners with deep
content expertise and a strong commitment to advancing knowledge and closing workforce gaps in Colorado’s bioscience
Business Partner of the Year: Phyllis Arthur, BIO
2014 Business Partner of the Year is Phyllis Arthur, Senior Director of Vaccines, Immunotherapeutics and Diagnostics Policy
at the Biotechnology Industry Organization. Ms. Arthur was a remarkable partner for CBSA on Senate Bill 222, becoming the
bioscience industry’s taskforce representative and also forging lasting relationships with the Colorado Department of
Public Health and Environment, the Colorado Children's Immunization Coalition and many other stakeholders. In the end, the
taskforce collectively - and unanimously – agreed to all of the recommendations for Colorado. Phyllis continues to remain
involved during the implementation phase and will act as a resource providing national best practice models and allowing the
State to leverage her relationships and knowledge base.
Educator of the Year: Deborah Carnevale
Deborah Carnevale is the Director of the Overland High School Biotechnology Program. Under her leadership,
the school’s biotechnology program has received multiple grants and certifications. Students who have completed the
program have an advantage when entering college. Their advanced research skills in biotechnology has enabled many of them
to receive laboratory jobs as university freshmen, a rare opportunity. Her dedication and commitment to her students is commendable.
Volunteer of the Year: Amy Wedeking Shannon
Ms. Shannon is Principal
Consultant for Caliber One Solutions and an active participant on CBSA’s Membership Committee. Her knowledge base and
relationships in the community have proven to be very valuable to the membership efforts of CBSA. Her drive is tireless and
capable when bringing new members into the organization. Amy also provides great leadership and insight through her recommendations
to better the committee process. In the words of Committee Chair (and 2013 Volunteer of the Year) Dustin Whistler, the committee
is very lucky to have her.
Chairman’s Award: Monisha Merchant
Merchant serves as Senior Policy Advisor to Senator Michael Bennet and has been a tremendous leader for the bioscience industry
and the State as a whole. During the development of the 2011 America Invents Act, Senator Bennet co-authored a provision to
establish three United States Satellite Patent and Trademark Offices. Ms. Merchant’s commitment to the goal of securing
a satellite office in Colorado was truly commendable. She helped to spearhead the process and forged an incredible coalition
of public and private partners which ultimately led to the selection of the Denver site. This achievement will not only better
the entrepreneurs in the state and also across the region. Ms. Merchant also played an integral role in leveraging her influence
and relationships to create the Blackstone Entrepreneurial Network (BEN) in Colorado. BEN links Master Entrepreneurs across
industries and regions to support high growth entrepreneurial activities. Most recently, she facilitated the “Bioscience
in Colorado” day where she and Senator Bennet invited key community leaders to explore the industry’s eco-system.
About the Awards Dinner
The Awards Dinner began with a cocktail
reception followed by dinner and the awards program. In addition, the Boettcher Foundation presented its 2014 Class of Boettcher
Investigators in the Webb-Waring Biomedical Research Program. The event closed with a keynote address by Olympic cycling medalist
and Parkinson’s survivor Davis Phinney.
Phinney, diagnosed with Parkinson’s disease
in 2000 at the age of 40, founded the Boulder-based Davis Phinney Foundation in 2004. Today, Phinney is both a role model
in the cycling community and an inspiration to the estimated 1.5 million Americans and estimated 10 million worldwide who
are currently living with the disease. Tens of thousands of people living with this disease have been directly touched by
one of the Davis Phinney Foundation programs or through Davis Phinney’s inspirational message: “it is possible
to live well with Parkinson’s today.” For more information, visit: http://www.davisphinneyfoundation.org andhttp://www.medtronicdbs.com/parkinsons/personal-stories/davis-phinney/index.htm.
Sponsors of the Awards Dinner included: Boettcher Foundation; Cooley, LLP; Fisher Scientific, Fitzsimons
Redevelopment Authority, Medtronic and Terumo BCT.